Xvivo Perfusion AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models

It's been a sad week for Xvivo Perfusion AB (publ) (STO:XVIVO), who've watched their investment drop 13% to kr246 in the week since the company reported its second-quarter result. It looks like a pretty bad result, all things considered. Although revenues of kr239m were in line with analyst predictions, statutory earnings fell badly short, missing estimates by 29% to hit kr0.52 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Following the latest results, Xvivo Perfusion's five analysts are now forecasting revenues of kr986.8m in 2026. This would be a notable 10% improvement in revenue compared to the last 12 months. Per-share earnings are expected to step up 10% to kr3.10. Yet prior to the latest earnings, the analysts had been anticipated revenues of kr987.0m and earnings per share (EPS) of kr3.50 in 2026. So there's definitely been a decline in sentiment after the latest results, noting the substantial drop in new EPS forecasts.

View our latest analysis for Xvivo Perfusion

The consensus price target held steady at kr337, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Xvivo Perfusion analyst has a price target of kr385 per share, while the most pessimistic values it at kr300. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 22% growth on an annualised basis. That is in line with its 25% annual growth over the past five years. Juxtapose this against our data, which suggests that other companies (with analyst coverage) in the industry are forecast to see their revenues grow 17% per year. It's clear that while Xvivo Perfusion's revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Xvivo Perfusion. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Xvivo Perfusion. Long-term earnings power is much more important than next year's profits. We have forecasts for Xvivo Perfusion going out to 2028, and you can see them free on our platform here.

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.